BioNeutra Global Corporation Announces Financial Results for Second Quarter Ended June 30, 2015

EDMONTON, ALBERTA--(Marketwired - Aug. 28, 2015) - BioNeutra Global Corporation ("BioNeutra" or the "Company") (CSE:BGA) is pleased to announce today its interim financial results for the three- month period ended June 30, 2015 (the "Second Quarter"). BioNeutra is a functional and health food ingredient manufacturer that uses its patented process to produce isomalto-oligosaccharide ("IMO") which is sold under its trademark VitaFiber™.

Second Quarter Highlights

• BioNeutra's revenues for the Second Quarter and the six-month period ended June 30, 2015 were $4,254,712 and $9,599,861 on gross margins of 42% and 50%, respectively. The Company's revenues during these periods were driven by strong sales of VitaFiber™ to food and beverage manufacturers targeting functional and health food markets and growing retail sales.
• Strong VitaFiber™ sales in the six-month period ended June 30, 2015 pushed the Company's Adjusted EBITDA to $2,291,317 as compared with $1,644,486 for the four-month period ended June 30, 2014.
• BioNeutra's strong Adjusted EBITDA has had a very positive effect on the operational strength of its balance sheet. At June 30, 2015, the Company had a cash balance of $4,186,822 and working capital of $6,991,546. The Company's cash balance and working capital have increased substantially year-over-year, from a cash balance of $1,190,600 and working capital of $2,903,747 at June 30, 2014.
• On April 23, 2015, BioNeutra, through its wholly-owned subsidiary BioNeutra North America Inc., entered into an agreement to purchase a mixed-use manufacturing and office building in Edmonton, Alberta, Canada. BioNeutra completed this purchase on August 21, 2015 and will now develop a commercial production line in this facility to produce functional food and beverage ingredients and products featuring IMO using the Company's patented IMO production processes. This IMO production line will be the first of its kind in North America and will make BioNeutra the exclusive North American producer of IMO products that feature Health Canada and European EFSA approval and FDA GRAS certification. This facility will also house BioNeutra's corporate head office and global training centre which will greatly expand its in-house research and development capabilities.
• On May 28, 2015, BioNeutra agreed to a private placement with a key strategic partner of 2,500,000 common shares at a price of $0.40 per common share for gross proceeds of $1,000,000. This private placement closed on July 15, 2015 and the Company intends to use the proceeds from this private placement for general working capital.
• On June 15, 2015, BioNeutra retained CHF Investor Relations ("CHF"), a highly-regarded Canadian investor relations firm with offices in Toronto and Calgary to assist the Company with investor relations and market making activities.

Second Quarter Financial Results